文献速递甲状腺疾病

孕早期抗甲状腺药物使用与出生缺陷风险

Maternal Thyroid Function, Use of Antithyroid Drugs in Early Pregnancy, and Birth Defects.
PubMed 文献 · J Clin Endocrinol Metab · 2019-01-01

基于丹麦全国性登记队列(1997-2016年,1243353名儿童)及两个含孕早期血样的出生队列,评估孕早期抗甲状腺药物暴露与出生缺陷风险。结果显示未暴露儿童出生缺陷频率为6.7%,甲巯咪唑/卡比马唑暴露后为9.6%,丙硫氧嘧啶暴露后为8.3%。母体甲状腺功能异常与出生缺陷风险无显著关联。

要点

  • 孕早期暴露于甲巯咪唑/卡比马唑或丙硫氧嘧啶的儿童出生缺陷频率高于未暴露儿童。
  • 母体甲状腺功能异常本身不是出生缺陷的主要风险因素。
  • 临床需权衡孕早期抗甲状腺药物治疗的获益与出生缺陷风险。

核心结论

  • 孕早期使用抗甲状腺药物与出生缺陷风险增加相关,而母体甲状腺功能异常本身不是出生缺陷的主要风险因素。

研究设计与样本

  • 全国性登记队列(NRBC)纳入1997-2016年1243353名儿童;丹麦国家出生队列(DNBC)纳入1997-2003年8830名儿童;北丹麦地区妊娠队列(NDRPC)纳入2011-2015年14483名儿童。

主要发现

  • NRBC中2718名(0.2%)儿童在孕早期暴露于抗甲状腺药物。
  • 未暴露儿童出生缺陷频率为6.7%(95%CI 6.7%-6.8%),甲巯咪唑/卡比马唑暴露后为9.6%(95%CI 8.2%-11.2%),丙硫氧嘧啶暴露后为8.3%(95%CI 6.7%-10.3%)。
  • DNBC中随机队列与出生缺陷病例的母体孕早期甲状腺功能异常频率分别为12.4%和12.6%(P=0.8)。
  • NDRPC中随机队列与出生缺陷病例的母体孕早期甲状腺功能异常频率分别为15.1%和15.4%(P=0.8)。

临床怎么用

  • 孕早期使用抗甲状腺药物时需评估出生缺陷风险,尤其甲巯咪唑/卡比马唑和丙硫氧嘧啶。
  • 不应将母体甲状腺功能异常本身视为出生缺陷的主要风险因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Antithyroid drug (ATD) therapy in early pregnancy is associated with birth defects, but more data are needed to substantiate the risk associated with different types of ATD. Furthermore, the role of abnormal maternal thyroid function per se remains unclarified. OBJECTIVE: To evaluate the risk of birth defects associated with the use of ATD in an extended nationwide cohort and the role of abnormal maternal thyroid function in birth cohorts including stored maternal blood samples from early pregnancy. PARTICIPANTS: Danish pregnant women and their live-born children, including 1,243,353 children from a Nationwide Register-Based Cohort (NRBC), 1997 to 2016; 8830 children from the Danish National Birth Cohort (DNBC), 1997 to 2003; and 14,483 children from the North Denmark Region Pregnancy Cohort (NDRPC), 2011 to 2015. MAIN OUTCOME MEASURES: Birth defects diagnosed before 2 years of age. RESULTS: In the NRBC, altogether 2718 (0.2%) children had been exposed to ATD in early pregnancy. The overall frequency of birth defects was 6.7% (95% CI, 6.7% to 6.8%) in nonexposed children and higher after exposure to methimazole/carbimazole (9.6%; 95% CI, 8.2% to 11.2%) and propylthiouracil (8.3%; 95% CI, 6.7% to 10.3%). On the other hand, the frequency of maternal thyroid dysfunction in early pregnancy was similar in the random cohort and in cases of birth defect in the DNBC (12.4 vs 12.6%, P = 0.8) and the NDRPC (15.1 vs 15.4%, P = 0.8). CONCLUSIONS: Results corroborate an increased risk of birth defects associated with the use of ATD in early pregnancy and suggest that abnormal maternal thyroid function is not a major risk factor for birth defects.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Andersen SL, Knøsgaard L, Olsen J, et al. Maternal Thyroid Function, Use of Antithyroid Drugs in Early Pregnancy, and Birth Defects. J Clin Endocrinol Metab. 2019. PMID: 31408173. doi:10.1210/jc.2019-01343

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。